Evidence map›Paper›PMID 26230832›Full record

ArticlePloS one2015

The Role of Angiotensin II and Cyclic AMP in Alveolar Active Sodium Transport.

Reem Ismael-Badarneh, Julia Guetta, Geula Klorin, Gidon Berger, Niroz Abu-Saleh, Zaid Abassi, Zaher S Azzam

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Do Changes inInternational journal of molecular sciences · 2021
    Review
  4. Article
  5. Effects of Anacardic Acid Monoene on the Respiratory System of Mice Submitted to Acute Respiratory Distress Syndrome.Revista brasileira de farmacognosia : orgao oficial da Sociedade Brasileira de Farmacognosia · 2021
    Article
  6. Candesartan could ameliorate the COVID-19 cytokine storm.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020
    Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Reem Ismael-BadarnehDepartment of Physiology, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Julia GuettaInternal Medicine "B", Rambam: Human Health Care Campus, Haifa, Israel.
Geula KlorinInternal Medicine "B", Rambam: Human Health Care Campus, Haifa, Israel.
Gidon BergerInternal Medicine "B", Rambam: Human Health Care Campus, Haifa, Israel; Department of Physiology, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Niroz Abu-SalehDepartment of Physiology, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Zaid AbassiDepartment of Physiology, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel.
Zaher S AzzamInternal Medicine "B", Rambam: Human Health Care Campus, Haifa, Israel; Department of Physiology, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel; The Rappaport Family Institute for Research in the Medical Sciences, Technion, Israel Institute of Technology, Haifa, Israel.
Technion – Israel Institute of Technology · ILRambam Health Care Campus · ILRappaport Family Institute for Research in the Medical Sciences · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Active alveolar fluid clearance is important in keeping airspaces free of edema. Angiotensin II plays a role in the pathogenesis of hypertension, heart failure and others. However, little is known about its contribution to alveolar fluid clearance. Angiotensin II effects are mediated by two specific receptors; AT1 and AT2. The localization of these two receptors in the lung, specifically in alveolar epithelial cells type II, was recently reported. We hypothesize that Angiotensin II may have a role in the regulation of alveolar fluid clearance. We investigated the effect of Angiotensin II on alveolar fluid clearance in rats using the isolated perfused lung model and isolated rat alveolar epithelial cells. The rate of alveolar fluid clearance in control rats was 8.6% ± 0.1 clearance of the initial volume and decreased by 22.5%, 28.6%, 41.6%, 48.7% and 39% in rats treated with 10-10 M, 10-9 M, 10-8 M, 10-7 M or 10-6 M of Ang II respectively (P < 0.003). The inhibitory effect of Angiotensin II was restored in losartan, an AT1 specific antagonist, pretreated rats, indicating an AT1 mediated effect of Ang II on alveolar fluid clearance. The expression of Na,K-ATPase proteins and cAMP levels in alveolar epithelial cells were down-regulated following the administration of Angiotensin II; suggesting that cAMP may be involved in AngII-induced reduced Na,K-ATPase expression, though the contribution of additional factors could not be excluded. We herein suggest a novel mechanism of clinical relevance by which angiotensin adversely impairs the ability of the lungs to clear edema.

Indexed as

AmilorideAngiotensin IIAnimalsCyclic AMPIon TransportMaleOuabainPulmonary AlveoliRatsRats, Sprague-DawleySodiumSodium-Potassium-Exchanging ATPaseAmilorideAngiotensin IICyclic AMPOuabainSodiumSodium-Potassium-Exchanging ATPase

Identifiers

PMID26230832
PMCPMC4521808
OpenAlexW2257418120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.